Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Recombinant Von Willebrand factor

Phase 1Small molecule

BBaxalta now part of Shire

1

Indications

5

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

ECMORecruiting

ECMOPhase 1

Recruiting

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

ECMO

NCT06118372

Clinical

Trials by Indication[1]

Von Willebrand disease4 trials

Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial

Completed·NNicoletta C Machin·Phase 3·NCT04344860·20 enrolled

Minimize Menorrhagia in Women With Von Willebrand Disease

Terminated·MMargaret Ragni·Phase 3·NCT02606045·39 enrolled

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Completed·BBaxalta now part of Shire·Phase 3·NCT01410227·49 enrolled

Show 1 more trial

Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery

Completed·BBaxalta now part of Shire·Phase 3·NCT02283268·24 enrolled

ECMO1 trial

Recombinant vWF Concentrate and ECMO

Recruiting·UUniversity of Virginia·Phase 1·NCT06118372·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Recombinant Von Willebrand factor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Von Willebrand factor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Von Willebrand factor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Baxalta now part of Shire company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBaxalta now part of Shire

Related News